CliffBio
small molecule

IMATINIB MESYLATE

IMATINIB MESYLATE

Loss of exclusivity—loss of exclusivity
CompanyShilpa Medicare →See this company's full patent-cliff portfolio

Drug detail

Brand nameIMATINIB MESYLATE
Active ingredientIMATINIB MESYLATE
StrengthEQ 100MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2019
Marketing statusRX

More from Shilpa Medicare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

IMATINIB MESYLATE patent cliff — loss of exclusivity — | CliffBio